Deutsche Bank Ag\ Viracta Therapeutics, Inc. Transaction History

Deutsche Bank Ag\

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 15, 2023	SELL	$1.38 - $2.29 $10,976 - $18,214	-7,954 Reduced 50.08%	7,928 $12,000
Q2 2022 Aug 11, 2022	SELL	$1.87 - $5.0 $7,104 - $18,995	-3,799 Reduced 19.3%	15,882 $62,000
Q1 2022 May 13, 2022	SELL	$2.23 - $4.76 $5,213 - $11,128	-2,338 Reduced 10.62%	19,681 $94,000
Q4 2021 Feb 11, 2022	BUY	$3.37 - $7.91 $3,929 - $9,223	1,166 Added 5.59%	22,019 $80,000
Q3 2021 Nov 04, 2021	SELL	$7.84 - $12.53 $5,260 - $8,407	-671 Reduced 3.12%	20,853 $167,000

Q2 2021 Aug 11, 2021	BUY	$7.55 - $12.95 $162,506 - $278,735	21,524 New	21,524 $244,000

9.39M

5.9K

Ticker VIRX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 37,558,200
Market Cap $18.4M
Description
Viracta Therapeutics, Inc., a precision oncology company, engages in developing drugs for the treatment of virus-associated malignancies. Its lead product candidature includes Nana-val, in combination with nanatinostat and valganciclovir that is in Phase II clinical trial for Epstein-Barr virus-positive lymphoma; and open-label Phase 2 basket tr...

Get notified when there are updates to the investment portfolio of Deutsche Bank Ag\, based on Form 13F filings with the SEC.

Stay updated on Deutsche Bank Ag\ with notifications on news.